Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.60 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 2/20 | 0.57 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | MC3R | P41968 | 1/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484442 | 1.00 | CYP2A6 (0.60) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| Hydrochloric Acid SCHEMBL28694005 | 0.98 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| Bromide SCHEMBL31513720 | 0.98 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| Hydrochloric Acid SCHEMBL308711 | 0.98 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL25418645 | 0.93 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL3718291 | 0.93 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL29454377 | 0.93 | ASIC3 (0.58) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL9016348 | 0.89 | ASIC3 (0.57) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL28498541 | 0.88 | HTR2A (0.59) | CYP2A6ASIC3CYP1A2MC4RMC5R | |
| SCHEMBL29463734 | 0.87 | CYP2A6 (0.52) | CYP2A6ASIC3CYP1A2MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12075637-B2 | Perovskite solar cell and fabrication method thereof | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2024-08-27 | — | — | US | claimed |
| CN-117859209-A | Perovskite solar cell and preparation method thereof | 宁德时代新能源科技股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-4300602-A1 | PEROVSKITE SOLAR CELL AND PREPARATION METHOD THEREFOR | Contemporary Amperex Technology Co., Limited (CN) | 2024-01-03 | — | — | EP | claimed |
| US-20230403869-A1 | PEROVSKITE SOLAR CELL AND FABRICATION METHOD THEREOF | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2023-12-14 | — | — | US | claimed |
| WO-2023216132-A1 | PEROVSKITE SOLAR CELL AND PREPARATION METHOD THEREFOR | 宁德时代新能源科技股份有限公司 | 2023-11-16 | — | — | WO | claimed |
| CN-112759533-A | Method for generating nitrile by catalyzing amine oxidation through nonmetal mesoporous nitrogen-doped carbon material | 中国科学院大连化学物理研究所 | 2021-05-07 | — | — | CN | claimed |
| CN-111916571-A | Red perovskite light emitting diode based on mixed halogen and preparation method thereof | 华南理工大学 | 2020-11-10 | — | — | CN | claimed |
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | ROSSI CRISTINA | 2008-08-28 | — | — | US | claimed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | claimed |
| EP-1868997-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | Menarini International Operations Luxembourg S.A. (LU) | 2007-12-26 | — | — | EP | claimed |
| WO-2006097460-A1 | HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2006-09-21 | — | — | WO | claimed |
| CN-1230431-C | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2005-12-07 | — | — | CN | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| EP-1132370-A2 | Process for producing n-substituted polyhydroxy nitrogen-containing heterocyles | MONSANTO COMPANY (US) | 2001-09-12 | — | — | EP | claimed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | CYP2A6 607/4885ASIC3 1556/4885CYP1A2 827/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | CYP2A6 2515/4885ASIC3 4736/4885CYP1A2 2133/4885 |
| US-20080207694-A1 | Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them | HDAC1, HDAC8, HDAC9 | CYP2A6 2796/4885ASIC3 1433/4885CYP1A2 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.